EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 156 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $927,152 | -49.6% | 47,693 | -26.5% | 0.00% | -100.0% |
| Q1 2023 | $1,840,560 | +193.6% | 64,877 | +202.5% | 0.00% | – |
| Q4 2022 | $626,896 | +11.7% | 21,447 | +69.9% | 0.00% | – |
| Q2 2022 | $561,000 | +21.4% | 12,620 | +35.1% | 0.00% | – |
| Q1 2022 | $462,000 | +18.2% | 9,342 | +21.5% | 0.00% | – |
| Q4 2021 | $391,000 | +32.5% | 7,687 | +45.4% | 0.00% | – |
| Q3 2021 | $295,000 | -19.8% | 5,288 | -33.1% | 0.00% | – |
| Q4 2020 | $368,000 | -4.9% | 7,900 | -13.3% | 0.00% | – |
| Q3 2020 | $387,000 | +82.5% | 9,114 | +126.7% | 0.00% | -100.0% |
| Q1 2018 | $212,000 | -12.4% | 4,021 | +30.8% | 0.00% | 0.0% |
| Q2 2017 | $242,000 | +10.0% | 3,073 | +15.8% | 0.00% | 0.0% |
| Q1 2017 | $220,000 | -37.7% | 2,653 | -70.8% | 0.00% | -50.0% |
| Q2 2016 | $353,000 | -56.7% | 9,100 | -54.8% | 0.00% | -50.0% |
| Q1 2016 | $815,000 | +64.3% | 20,112 | +200.2% | 0.00% | +33.3% |
| Q3 2015 | $496,000 | +15.1% | 6,699 | +25.8% | 0.00% | 0.0% |
| Q2 2015 | $431,000 | +26.8% | 5,327 | -34.4% | 0.00% | 0.0% |
| Q1 2015 | $340,000 | – | 8,125 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |